Adoptively	O
transferred	O
natural	B:C0022688
killer	I:C0022688
cells	I:C0022688
maintain	O
long	O
-	O
term	O
antitumor	O
activity	I:C0243095
by	O
epigenetic	O
imprinting	I:C0242614
and	O
CD4	O
(+	I:C0039215
)	I:C0039215

Adoptively	O
transferred	O
natural	O
killer	I:C0022688
cells	I:C0022688
maintain	O
long	O
-	O
term	O
antitumor	B:C0243095
activity	I:C0243095
by	O
epigenetic	O
imprinting	I:C0242614
and	O
CD4	O
(+	I:C0039215
)	I:C0039215

Adoptively	O
transferred	O
natural	O
killer	I:C0022688
cells	I:C0022688
maintain	O
long	O
-	O
term	O
antitumor	O
activity	I:C0243095
by	O
epigenetic	B:C0242614
imprinting	I:C0242614
and	O
CD4	O
(+	I:C0039215
)	I:C0039215

Adoptively	O
transferred	O
natural	O
killer	I:C0022688
cells	I:C0022688
maintain	O
long	O
-	O
term	O
antitumor	O
activity	I:C0243095
by	O
epigenetic	O
imprinting	I:C0242614
and	O
CD4	B:C0039215
(+	I:C0039215
)	I:C0039215

Natural	B:C0022688
killer	I:C0022688
(	I:C0022688
NK	I:C0022688
)	I:C0022688
cell	I:C0022688
infusions	O
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	O
.	O

Natural	O
killer	I:C0022688
(	I:C0022688
NK	I:C0022688
)	I:C0022688
cell	I:C0022688
infusions	B:C0574032
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	O
.	O

Natural	O
killer	I:C0022688
(	I:C0022688
NK	I:C0022688
)	I:C0022688
cell	I:C0022688
infusions	O
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	B:C0006826
.	O

The	O
optimal	O
strategies	O
for	O
NK	B:C0022688
cell	I:C0022688
activation	O
prior	O
to	O
infusion	O
are	O
still	O
under	O
debate	O
.	O

The	O
optimal	O
strategies	O
for	O
NK	O
cell	I:C0022688
activation	B:C1326120
prior	O
to	O
infusion	O
are	O
still	O
under	O
debate	O
.	O

The	O
optimal	O
strategies	O
for	O
NK	O
cell	I:C0022688
activation	O
prior	O
to	O
infusion	B:C0574032
are	O
still	O
under	O
debate	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	B:C0022688
cells	I:C0022688
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	O
cells	I:C0022688
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B:C0079189
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	O
cells	I:C0022688
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	O
cells	I:C0022688
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	B:C0254610
/	O
18	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	O
cells	I:C0022688
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	B:C0383327
.	O

The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long	O
-	O
term	O
NK	B:C0022688
cell	I:C0022688
antitumor	O
activity	I:C0243095
are	O
incompletely	O
under	O
-	O
stood	O
.	O

The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
antitumor	B:C0243095
activity	I:C0243095
are	O
incompletely	O
under	O
-	O
stood	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	B:C0022688
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	B:C3850137
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	B:C0254610
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	B:C0383327
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	B:C0254610
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	B:C0243095
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	B:C0024312
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	B:C1419248
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	O
cells	I:C0022688
preactivated	O
in	O
vitro	I:C3850137
with	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL	O
-	I:C0254610
15	I:C0254610
alone	O
,	O
maintained	O
high	O
antitumor	O
activity	I:C0243095
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	B:C0026809
.	O

The	O
NK	B:C0022688
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	B:C0021745
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	B:C0021920
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	B:C0021920
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	B:C1334085
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	B:C1708726
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B:C0040649
of	O
Ifng	O
.	O

The	O
NK	O
cell	I:C0022688
intrinsic	O
ability	O
for	O
IFN	O
γ	I:C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	O
sequence	I:C0021920
(	O
conserved	O
non-coding	I:C0021920
sequence	I:C0021920
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	B:C1334085
.	O

In	O
a	O
xenograft	B:C0012644
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	B:C0086418
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	B:C0254610
/	O
18	O
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	B:C0383327
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
-	O
preactivated	O
NK	B:C0022688
cells	I:C0022688
rejected	O
tumors	O
more	O
efficiently	O
.	O

In	O
a	O
xenograft	O
melanoma	I:C0012644
mouse	I:C0012644
model	I:C0012644
,	O
human	O
IL	O
-	I:C0123759
12	I:C0123759
/	O
15	O
/	O
18	O
-	O
preactivated	O
NK	O
cells	I:C0022688
rejected	O
tumors	B:C0027651
more	O
efficiently	O
.	O

In	O
RAG	B:C1419248
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
,	O
co-transfer	O
of	O
CD4	O
(+	I:C0039215
)	I:C0039215

In	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	B:C0026809
,	O
co-transfer	O
of	O
CD4	O
(+	I:C0039215
)	I:C0039215

In	O
RAG	O
-	I:C1419248
2(-/-)	I:C1419248
γc(-/-)	O
mice	O
,	O
co-transfer	O
of	O
CD4	B:C0039215
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cells	I:C0039215
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	B:C0022688
cells	I:C0022688
for	O
IFN	O
γ	I:C0021745
production	O
that	O
was	O
dependent	O
on	O
IL	O
-	I:C0021756
2.	I:C0021756
CD4	O
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cells	I:C0039215
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	O
cells	I:C0022688
for	O
IFN	B:C0021745
γ	I:C0021745
production	O
that	O
was	O
dependent	O
on	O
IL	O
-	I:C0021756
2.	I:C0021756
CD4	O
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cells	I:C0039215
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	O
cells	I:C0022688
for	O
IFN	O
γ	I:C0021745
production	O
that	O
was	O
dependent	O
on	O
IL	B:C0021756
-	I:C0021756
2.	I:C0021756
CD4	O
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cells	I:C0039215
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	O
cells	I:C0022688
for	O
IFN	O
γ	I:C0021745
production	O
that	O
was	O
dependent	O
on	O
IL	O
-	I:C0021756
2.	I:C0021756
CD4	B:C0039215
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cell	I:C0039215
activation	B:C1326120
during	O
homeostatic	O
proliferation	I:C1326161
required	O
macrophages	O
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
antitumor	O
activity	I:C0243095
.	O

T	I:C0039215
cell	I:C0039215
activation	O
during	O
homeostatic	B:C1326161
proliferation	I:C1326161
required	O
macrophages	O
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
antitumor	O
activity	I:C0243095
.	O

T	I:C0039215
cell	I:C0039215
activation	O
during	O
homeostatic	O
proliferation	I:C1326161
required	O
macrophages	B:C0024432
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
antitumor	O
activity	I:C0243095
.	O

T	I:C0039215
cell	I:C0039215
activation	O
during	O
homeostatic	O
proliferation	I:C1326161
required	O
macrophages	O
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	B:C0022688
cell	I:C0022688
antitumor	O
activity	I:C0243095
.	O

T	I:C0039215
cell	I:C0039215
activation	O
during	O
homeostatic	O
proliferation	I:C1326161
required	O
macrophages	O
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
antitumor	B:C0243095
activity	I:C0243095
.	O

Thus	O
,	O
NK	B:C0022688
cells	I:C0022688
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	O
by	O
epigenetic	O
imprinting	I:C0242614
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFN	O
γ	I:C0021745
-	O
producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O

Thus	O
,	O
NK	O
cells	I:C0022688
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	B:C0079189
by	O
epigenetic	O
imprinting	I:C0242614
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFN	O
γ	I:C0021745
-	O
producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O

Thus	O
,	O
NK	O
cells	I:C0022688
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	O
by	O
epigenetic	B:C0242614
imprinting	I:C0242614
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFN	O
γ	I:C0021745
-	O
producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O

Thus	O
,	O
NK	O
cells	I:C0022688
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	O
by	O
epigenetic	O
imprinting	I:C0242614
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFN	B:C0021745
γ	I:C0021745
-	O
producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O

In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B:C0079189
-	O
preactivated	O
NK	O
cells	I:C0022688
with	O
CD4	O
(+	I:C0039215
)	I:C0039215

In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	O
-	O
preactivated	O
NK	B:C0022688
cells	I:C0022688
with	O
CD4	O
(+	I:C0039215
)	I:C0039215

In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	O
-	O
preactivated	O
NK	O
cells	I:C0022688
with	O
CD4	B:C0039215
(+	I:C0039215
)	I:C0039215

T	I:C0039215
cell	I:C0039215
activation	B:C1326120
upon	O
lymphopenic	O
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
effector	O
function	O
for	O
cancer	O
immunotherapy	I:C0278348
.	O

T	I:C0039215
cell	I:C0039215
activation	O
upon	O
lymphopenic	B:C0024312
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
effector	O
function	O
for	O
cancer	O
immunotherapy	I:C0278348
.	O

T	I:C0039215
cell	I:C0039215
activation	O
upon	O
lymphopenic	O
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	B:C0022688
cell	I:C0022688
effector	O
function	O
for	O
cancer	O
immunotherapy	I:C0278348
.	O

T	I:C0039215
cell	I:C0039215
activation	O
upon	O
lymphopenic	O
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	O
cell	I:C0022688
effector	O
function	O
for	O
cancer	B:C0278348
immunotherapy	I:C0278348
.	O

